Eleva appoints Erich Rajkovic as new Chief Business Officer
Eleva appoints Erich Rajkovic as new Chief Business Officer [...]
Eleva advances CPV-104 into Phase 1b clinical testing in patients with C3G, following the successful completion of single ascending dose evaluation in healthy volunteers
Eleva advances CPV-104 into Phase 1b clinical testing in [...]
Eleva administers first dose of its Factor H biological treatment in C3-Glomerulopathy to healthy volunteers
Eleva administers first dose of its Factor H biological [...]
